Jane Street’s Aldeyra Therapeutics ALDX Stock Holding History

Jane Street’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$180K	Buy	106,300 +49,100	+86%	+$215K	﹤0.01%	10253
2025 Q4	$296K	Buy	57,200 +23,000	+67%	+$118K	﹤0.01%	8866
2025 Q3	$179K	Buy	34,200 +7,600	+29%	+$39.6K	﹤0.01%	9761
2025 Q2	$102K	Buy	+26,600	New	+$68.8K	﹤0.01%	8945
2023 Q3	–	Sell	-14,800	Closed	-$124K	–	8548
2023 Q2	$124K	Buy	+14,800	New	+$146K	﹤0.01%	7909
2022 Q4	–	Sell	-41,200	Closed	-$220K	–	9049
2022 Q3	$220K	Buy	+41,200	New	+$247K	﹤0.01%	8023
2022 Q2	–	Sell	-22,700	Closed	-$101K	–	9560
2022 Q1	$101K	Sell	22,700 -55,200	-71%	-$220K	﹤0.01%	9453
2021 Q4	$312K	Buy	77,900 +55,600	+249%	+$424K	﹤0.01%	8091
2021 Q3	$196K	Sell	22,300 -22,200	-50%	-$204K	﹤0.01%	8864
2021 Q2	$504K	Buy	44,500 +31,300	+237%	+$376K	﹤0.01%	7221
2021 Q1	$157K	Buy	+13,200	New	+$152K	﹤0.01%	8437

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street's ALDX Position: Q1 2026 in Review

Jane Street increased its Aldeyra Therapeutics (ALDX) stake by 219% in Q1 2026, buying an estimated $2.91M and bringing the position to 968,891 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #5465.

Jane Street first reported a position in ALDX in Q3 2017 and has held it in 21 quarters since. The position peaked at $2.68M in Q1 2023. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

Jane Street held 968,891 shares of Aldeyra Therapeutics worth $1.64M as of Q1 2026.
Jane Street bought 665,039 Aldeyra Therapeutics shares in Q1 2026, an estimated $2.91M.
Aldeyra Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5465 holding.
Jane Street first reported a position in Aldeyra Therapeutics in Q3 2017 and has held it in 21 quarters since.
Jane Street's Aldeyra Therapeutics position peaked at $2.68M in Q1 2023.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.